Clinical trial / 2013
Yeast beta-glucan supplementation reduced symptomatic common cold infections by 25% in healthy participants with recurring infections.
In a double-blind, randomized, multicentric trial, 162 healthy participants with recurring infections took 900 mg daily of either placebo (n = 81) or an insoluble brewers' yeast (1,3)-(1,6)-beta-D-glucan preparation (n = 81) for 16 weeks. In the per-protocol population, yeast beta-glucan reduced symptomatic common cold infections by 25% compared to placebo (p = 0.041). The mean symptom score was 15% lower with beta-glucan (p = 0.125), and beta-glucan significantly reduced sleep difficulties caused by cold episodes (p = 0.028). Efficacy was rated better for beta-glucan than placebo by both physicians (p = 0.004) and participants (p = 0.012).
- Study type
- Double-blind, randomized, placebo-controlled, multicentric trial
- Who was studied
- 162 healthy participants with recurring infections
- What was measured
- Number of common cold episodes, infection symptom scores, sleep difficulties, and efficacy ratings
THE PAPER
Yeast (1,3)-(1,6)-beta-glucan helps to maintain the body's defence against pathogens: a double-blind, randomized, placebo-controlled, multicentric study in healthy subjects.
Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Eur J Nutr, 2013.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.